Quintrio
Home

SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

MaxCyte, Inc. Common Stock

MXCT

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Last trade $1.20
Day change +$0.02 (+1.69%)
Day range $1.17 – $1.26
Volume 777,901
Market cap $122M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$121.84M
Price / earnings
—
Price / book
0.81×
Price / sales
3.54×
EV / sales
3.16×
EV / EBITDA
-4.7×

Profitability

Earnings per share
-$0.27
Return on assets
-15.33%
Return on equity
-18.54%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.83×
Quick ratio
7.37×
Cash ratio
0.84×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.45M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MXCT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$10.15M$7.27M$9.65M$7.3M$6.83M$8.51M$10.39M$8.69M
Cost of revenue$1.68M$1.68M$1.57M$1.61M$1.6M$1.52M$1.5M$2.28M
Gross profit$8.47M$5.6M$8.08M$5.69M$5.23M$6.99M$8.89M$6.41M
Selling, general and administrative$10.77M$10.62M$9.39M$8.99M$9.96M$13.87M$14.22M$13.68M
Research and development$2.87M$4.25M$3.86M$3.34M$5.32M$6.27M$5.9M$4.61M
Total operating expenses$14.51M$15.83M$14.27M$16.92M$19.38M$21.22M$21.19M$19.31M
Operating income-$6.04M-$10.23M-$6.19M-$11.23M-$14.15M-$14.23M-$12.3M-$12.9M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.76M-$8.87M-$4.75M-$9.6M-$12.42M-$12.36M-$10.26M-$10.6M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.76M-$8.87M-$4.75M-$9.6M-$12.42M-$12.36M-$10.26M-$10.6M
Net income attributable to common shareholders-$4.76M-$8.87M-$4.75M-$9.6M-$12.42M-$12.36M-$10.26M-$10.6M
EBITDA-$5.14M-$9.25M-$5.14M-$3.54M-$10.02M-$13.13M-$11.2M-$11.84M
Basic earnings per share-$0.05-$0.08-$0.04-$0.09-$0.12-$0.12-$0.10-$0.10
Diluted earnings per share-$0.05-$0.08-$0.04-$0.09-$0.12-$0.12-$0.10-$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates

Keros Therapeutics reported Q3 2026 earnings of $0.7 per share, beating consensus estimates of a $0.96 loss, with a 172.92% earnings surprise. Revenues reached $40.01 million, surpassing estimates by 197.47% compared to $14.26 million year-ago. However, the stock has underperformed the market, down 46.8% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates

Fortrea Holdings Inc. (FTRE) reported Q3 earnings of $0.28 per share, beating consensus estimates of $0.24, and revenues of $691.5 million, exceeding expectations by 3.18%. The company has outperformed the market by 50% year-to-date versus the S&P 500's 13.1% gain. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.

GlobeNewswire Inc.

North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity

The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.

Benzinga

Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)

U.S. stock futures showed mixed performance on Wednesday with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose. President Trump visited China with major tech leaders including Nvidia's Jensen Huang, Tesla's Elon Musk, and Apple's Tim Cook. Key movers included Nextpower surging on strong earnings, MaxCyte jumping on better-than-expected results, and Red Cat Holdings plunging after a public offering announcement. The 10-year Treasury yield stood at 4.46%, with markets pricing a 97.6% likelihood of unchanged Fed rates in June.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.